Alder Biopharmaceuticals (ALDR) Receives New Coverage from Analysts at Stifel Nicolaus

Stock analysts at Stifel Nicolaus initiated coverage on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Tuesday. The firm set a “buy” rating and a $30.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price indicates a potential upside of 56.25% from the company’s current price.

Several other brokerages have also issued reports on ALDR. ValuEngine upgraded shares of Alder Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, June 5th. BidaskClub lowered shares of Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 24th. Piper Jaffray Companies started coverage on shares of Alder Biopharmaceuticals in a research note on Monday. They issued an “overweight” rating and a $28.00 price target on the stock. Canaccord Genuity set a $20.00 price target on shares of Alder Biopharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 21st. Finally, Zacks Investment Research lowered shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $22.40.

Alder Biopharmaceuticals opened at $19.20 on Tuesday, according to MarketBeat.com. The company has a market cap of $1.29 billion, a PE ratio of -3.88 and a beta of 2.66. The company has a debt-to-equity ratio of 0.57, a current ratio of 13.31 and a quick ratio of 13.30. Alder Biopharmaceuticals has a 1-year low of $8.60 and a 1-year high of $19.95.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.50). equities analysts predict that Alder Biopharmaceuticals will post -4.97 earnings per share for the current year.

In other Alder Biopharmaceuticals news, insider Mark James Litton sold 22,727 shares of Alder Biopharmaceuticals stock in a transaction on Friday, June 1st. The shares were sold at an average price of $17.84, for a total value of $405,449.68. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeffrey T. L. Smith sold 12,161 shares of Alder Biopharmaceuticals stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $15.03, for a total transaction of $182,779.83. Following the completion of the sale, the insider now owns 5,871 shares in the company, valued at $88,241.13. The disclosure for this sale can be found here. Insiders sold a total of 114,248 shares of company stock worth $1,967,874 over the last quarter. Company insiders own 17.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. increased its stake in shares of Alder Biopharmaceuticals by 74.3% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 176,000 shares of the biopharmaceutical company’s stock worth $2,235,000 after purchasing an additional 75,000 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Alder Biopharmaceuticals by 1.5% during the 4th quarter. Bank of New York Mellon Corp now owns 320,029 shares of the biopharmaceutical company’s stock worth $3,664,000 after purchasing an additional 4,873 shares during the last quarter. Teachers Advisors LLC increased its stake in shares of Alder Biopharmaceuticals by 27.7% during the 4th quarter. Teachers Advisors LLC now owns 120,931 shares of the biopharmaceutical company’s stock worth $1,385,000 after purchasing an additional 26,233 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Alder Biopharmaceuticals by 138.3% during the 4th quarter. TIAA CREF Investment Management LLC now owns 394,589 shares of the biopharmaceutical company’s stock worth $4,518,000 after purchasing an additional 229,010 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of Alder Biopharmaceuticals during the 2nd quarter worth about $198,000.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Featured Story: Book Value Per Share – BVPS

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply